GLP1R and metabolic dysfunction-associated steatohepatitis: However, the ESSENCE and LIVERAGETM trials will serve to be a useful barometer for the efficacy of a GLP-1 agonist in both obese and non-obese MASH patients without Type 2 Diabetes (T2D).